Fifty percent of CRLF2-rearranged Down syndrome–associated ALL cases have concomitant JAK mutations (commonly a JAK2 R683G point mutation)83, but JAK inhibitors have yet to be formally evaluated in clinical trials. The gene discussed is CRLF2; the disease is Down syndrome.